EvolveImmune Therapeutics, Inc.
EvolveImmune Therapeutics is an innovative immuno-oncology company focused on developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency in solid tumors and hematological cancers. The company is advancing a pipeline of novel T cell engager platforms, notably EVOLVE104, which targets tumor antigens with integrated CD2 co-stimulation, aiming to improve treatment outcomes and address unmet medical needs in oncology.
Industries
Nr. of Employees
small (1-50)
EvolveImmune Therapeutics, Inc.
Branford, Connecticut, United States, North America
Products
ULBP2-targeted multispecific T cell engager (lead clinical candidate)
A multispecific T cell engager designed to conditionally target ULBP2-family antigens on squamous-lineage and select solid tumors while providing integrated CD2 costimulation to enhance T cell activity and durability.
CD20-targeted 2:1 bispecific T cell engager with CD2 costimulation
A 2:1-format CD20-targeted multispecific engager designed for B cell malignancies and autoimmune indications that pairs tumor targeting with CD2 costimulatory engagement to improve potency and tolerability.
B7-H4-targeted T cell engager program for ER-low and TNBC
A multispecific T cell engager engineered to target B7-H4-expressing breast tumors (estrogen receptor-low and triple-negative subtypes) with integrated CD2 costimulation and potential for combination with other therapies.
ULBP2-targeted multispecific T cell engager (lead clinical candidate)
A multispecific T cell engager designed to conditionally target ULBP2-family antigens on squamous-lineage and select solid tumors while providing integrated CD2 costimulation to enhance T cell activity and durability.
CD20-targeted 2:1 bispecific T cell engager with CD2 costimulation
A 2:1-format CD20-targeted multispecific engager designed for B cell malignancies and autoimmune indications that pairs tumor targeting with CD2 costimulatory engagement to improve potency and tolerability.
B7-H4-targeted T cell engager program for ER-low and TNBC
A multispecific T cell engager engineered to target B7-H4-expressing breast tumors (estrogen receptor-low and triple-negative subtypes) with integrated CD2 costimulation and potential for combination with other therapies.
Services
Translational research collaborations
Collaborative translational studies with clinical and academic partners to characterize tumor antigen expression, immune infiltration and inform clinical patient selection.
CMC development and clinical manufacturing support
Chemistry, manufacturing and control activities to enable biologics scale-up, clinical supply chain planning, and CDMO coordination for first-in-human studies.
Preclinical pharmacology and safety studies
Preclinical efficacy, safety, PK and toxicology study execution including comparative benchmarking, cytokine release evaluation, and non-clinical model testing to support IND-enabling packages.
Translational research collaborations
Collaborative translational studies with clinical and academic partners to characterize tumor antigen expression, immune infiltration and inform clinical patient selection.
CMC development and clinical manufacturing support
Chemistry, manufacturing and control activities to enable biologics scale-up, clinical supply chain planning, and CDMO coordination for first-in-human studies.
Preclinical pharmacology and safety studies
Preclinical efficacy, safety, PK and toxicology study execution including comparative benchmarking, cytokine release evaluation, and non-clinical model testing to support IND-enabling packages.
Expertise Areas
- Immuno-oncology drug discovery
- Multispecific antibody engineering
- Preclinical pharmacology and safety assessment
- Translational biomarker development and patient selection
Key Technologies
- CRISPR-Cas9 in vivo screening
- Multispecific (trispecific/bispecific) antibody engineering
- 2:1 bispecific antibody formats
- Supported lipid bilayer immunological synapse assays